{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:09:38Z","timestamp":1761523778646,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T00:00:00Z","timestamp":1562889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T00:00:00Z","timestamp":1562889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Amgen (Europe) GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s40268-019-0278-8","type":"journal-article","created":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T10:03:59Z","timestamp":1562925839000},"page":"267-275","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab"],"prefix":"10.1007","volume":"19","clinical-trial-number":[{"clinical-trial-number":"nct00508404","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Claus-Henning","family":"K\u00f6hne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meinolf","family":"Karthaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Mineur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef","family":"Thaler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Van den Eynde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0584-1242","authenticated-orcid":false,"given":"Javier","family":"Gallego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reija","family":"Koukakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marloes","family":"Berkhout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf-Dieter","family":"Hofheinz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,12]]},"reference":[{"key":"278_CR1","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386\u2013422.","journal-title":"Ann Oncol"},{"key":"278_CR2","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines in oncology: colon cancer. Version 2. 2019. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon_blocks.pdf. Accessed 13 June 2019."},{"key":"278_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00432-011-1061-6","volume":"138","author":"CH Kohne","year":"2012","unstructured":"Kohne CH, Hofheinz R, Mineur L, Letocha H, Greil R, Thaler J, et al. First-line panitumumab plus irinotecan\/5-fluorouracil\/leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol. 2012;138:65\u201372.","journal-title":"J Cancer Res Clin Oncol"},{"key":"278_CR4","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/bjc.2016.343","volume":"115","author":"M Karthaus","year":"2016","unstructured":"Karthaus M, Hofheinz R-D, Mineur L, Letocha H, Greil R, Thaler J, et al. Impact of tumour RAS\/BRAF status in a first-line study of panitumumab\u2009+\u2009FOLFIRI in patients with metastatic colorectal cancer. Br J Cancer. 2016;115:1215\u201322.","journal-title":"Br J Cancer"},{"key":"278_CR5","unstructured":"European Medicines Agency. Vectibix\u00ae (panitumumab): summary of product characteristics. 2018. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000741\/WC500047710.pdf. Accessed 13 June 2019."},{"key":"278_CR6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00280-016-3196-2","volume":"79","author":"J Hu","year":"2017","unstructured":"Hu J, Zhang Z, Zheng R, Cheng L, Yang M, Li L, et al. On-treatment markers as predictors to guide anti-EGFR MoAb treatment in metastatic colorectal cancer: a systematic review with meta-analysis. Cancer Chemother Pharmacol. 2017;79:275\u201385.","journal-title":"Cancer Chemother Pharmacol"},{"key":"278_CR7","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.ejca.2015.03.026","volume":"51","author":"JY Douillard","year":"2015","unstructured":"Douillard JY, Siena S, Peeters M, Koukakis R, Terwey JH, Tabernero J. Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer. 2015;51:1231\u201342.","journal-title":"Eur J Cancer"},{"key":"278_CR8","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41416-018-0165-z","volume":"119","author":"M Peeters","year":"2018","unstructured":"Peeters M, Price T, Taieb J, Geissler M, Rivera F, Canon J-L, et al. Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials. Br J Cancer. 2018;119:303\u201312.","journal-title":"Br J Cancer"},{"key":"278_CR9","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00432-017-2534-z","volume":"144","author":"J Taieb","year":"2017","unstructured":"Taieb J, Rivera F, Siena S, Karthaus M, Valladares-Ayerbes M, Gallego J, et al. Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in 3 randomised panitumumab trials. J Cancer Res Clin Oncol. 2017;144:321\u201335.","journal-title":"J Cancer Res Clin Oncol"},{"key":"278_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"278_CR11","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/j.ejca.2015.06.116","volume":"51","author":"V Heinemann","year":"2015","unstructured":"Heinemann V, Stintzing S, Modest DP, Giessen-Jung C, Michl M, Mansmann UR. Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). Eur J Cancer. 2015;51:1927\u201336.","journal-title":"Eur J Cancer"},{"key":"278_CR12","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/S1470-2045(16)30269-8","volume":"17","author":"S Stintzing","year":"2016","unstructured":"Stintzing S, Modest DP, Rossius L, Lerch MM, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol. 2016;17:1426\u201334.","journal-title":"Lancet Oncol"},{"key":"278_CR13","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1200\/JCO.2012.42.8532","volume":"31","author":"H Piessevaux","year":"2013","unstructured":"Piessevaux H, Buyse M, Schlichting M, Van Cutsem E, Bokemeyer C, Heeger S, Tejpar S. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol. 2013;31:3764\u201375.","journal-title":"J Clin Oncol"},{"key":"278_CR14","doi-asserted-by":"publisher","first-page":"e000041","DOI":"10.1136\/esmoopen-2016-000041","volume":"1","author":"S Siena","year":"2016","unstructured":"Siena S, Tabernero J, Bodoky G, Cunningham D, Rivera F, Ruff P, et al. Quality of life during first-line FOLFOX4\u2009\u00b1\u2009panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial. ESMO Open. 2016;1:e000041.","journal-title":"ESMO Open"},{"key":"278_CR15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ejca.2017.03.023","volume":"79","author":"S Stintzing","year":"2017","unstructured":"Stintzing S, Miller-Phillips L, Modest DP, Fischer von Weikersthal L, Decker T, Kiani A, et al. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. Eur J Cancer. 2017;79:50\u201360.","journal-title":"Eur J Cancer"},{"key":"278_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejca.2016.10.007","volume":"70","author":"JW Holch","year":"2017","unstructured":"Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V. The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer. 2017;70:87\u201398.","journal-title":"Eur J Cancer"},{"key":"278_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1001\/jamaoncol.2016.4227","volume":"3","author":"F Petrelli","year":"2017","unstructured":"Petrelli F, Tomasello G, Borgonovo K, Ghidini M, Turati L, Dallera P, et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol. 2017;3:211\u20139.","journal-title":"JAMA Oncol"},{"key":"278_CR18","doi-asserted-by":"publisher","first-page":"dju427","DOI":"10.1093\/jnci\/dju427","volume":"107","author":"F Loupakis","year":"2015","unstructured":"Loupakis F, Yang D, Yau L, Feng S, Cremolini C, Zhang W, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst. 2015;107:dju427.","journal-title":"J Natl Cancer Inst"},{"key":"278_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ejca.2017.07.016","volume":"84","author":"S Stintzing","year":"2017","unstructured":"Stintzing S, Tejpar S, Gibbs P, Thiebach L, Lenz HJ. Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. Eur J Cancer. 2017;84:69\u201380.","journal-title":"Eur J Cancer"},{"key":"278_CR20","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1200\/JCO.2016.34.15_suppl.3504","volume":"34","author":"AP Venook","year":"2016","unstructured":"Venook AP, Niedzwiecki D, Innocenti F, Fruth B, Greene C, O\u2019Neil BH, et al. Impact of primary tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB\/SWOG 80405 (Alliance). J Clin Oncol. 2016;34:3504.","journal-title":"J Clin Oncol"},{"key":"278_CR21","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ejso.2014.11.001","volume":"41","author":"GH Lee","year":"2015","unstructured":"Lee GH, Malietzis G, Askari A, Bernardo D, Al-Hassi HO, Clark SK. Is right-sided colon cancer different to left-sided colorectal cancer? A systematic review. Eur J Surg Oncol. 2015;41:300\u20138.","journal-title":"Eur J Surg Oncol"},{"key":"278_CR22","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1093\/annonc\/mdx119","volume":"28","author":"N Boeckx","year":"2017","unstructured":"Boeckx N, Koukakis R, de Beeck OK, Rolfo C, Van Camp G, Siena S, et al. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Ann Oncol. 2017;28:1862\u20138.","journal-title":"Ann Oncol"},{"key":"278_CR23","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jamaoncol.2016.3797","volume":"3","author":"S Tejpar","year":"2017","unstructured":"Tejpar S, Stintzing S, Ciardiello F, Taberno J, Van Cutsem E, Beier F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the crystal and fire-3 trials. JAMA Oncol. 2017;3:194\u2013201.","journal-title":"JAMA Oncol"},{"key":"278_CR24","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1634\/theoncologist.2016-0084","volume":"21","author":"R Moretto","year":"2016","unstructured":"Moretto R, Cremolini C, Rossini D, Pietrantonio F, Battaglin F, Mennitto A, et al. Location of primary tumor and benefit from anti-epidermal growth factor receptor monoclonal antibodies in patients with RAS and BRAF wild-type metastatic colorectal cancer. Oncologist. 2016;21:988\u201394.","journal-title":"Oncologist"},{"key":"278_CR25","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","volume":"28","author":"D Arnold","year":"2017","unstructured":"Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28:1713\u201329.","journal-title":"Ann Oncol"},{"key":"278_CR26","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.clcc.2018.03.005","volume":"17","author":"N Boeckx","year":"2018","unstructured":"Boeckx N, Koukakis R, Op de Beeck K, Rolfo C, Van Camp G, Siena S, et al. Effect of primary tumor location on second- or later-line treatment outcomes in patients with RAS wild-type metastatic colorectal cancer and all treatment lines in patients with RAS mutations in four randomized panitumumab studies. Clin Colorectal Cancer. 2018;17:170\u20138.","journal-title":"Clin Colorectal Cancer"},{"key":"278_CR27","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1200\/JCO.2018.36.4_suppl.820","volume":"36","author":"M Karthaus","year":"2018","unstructured":"Karthaus M, Eynde MVD, Mineur L, Thaler J, Koukakis R, Berkhout M, Gallego J. Impact of primary tumour location (PTL) on outcomes in patients (pts) with metastatic colorectal cancer (mCRC) undergoing first-line panitumumab (Pmab)\u2009+\u2009FOLFIRI treatment. J Clin Oncol. 2018;36:820.","journal-title":"J Clin Oncol"},{"key":"278_CR28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205\u201316.","journal-title":"J Natl Cancer Inst"},{"key":"278_CR29","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ejca.2017.04.024","volume":"81","author":"A Carrato","year":"2017","unstructured":"Carrato A, Abad A, Massuti B, Gravalos C, Escudero P, Longo-Munoz F, Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), et al. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: a randomised, phase II trial (PLANET-TTD). Eur J Cancer. 2017;81:191\u2013202.","journal-title":"Eur J Cancer."},{"key":"278_CR30","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408\u201317.","journal-title":"N Engl J Med"},{"key":"278_CR31","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.1002\/cncr.26086","volume":"117","author":"B Tran","year":"2011","unstructured":"Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011;117:4623\u201332.","journal-title":"Cancer"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-019-0278-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-019-0278-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-019-0278-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:50:48Z","timestamp":1628617848000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-019-0278-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,12]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["278"],"URL":"https:\/\/doi.org\/10.1007\/s40268-019-0278-8","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"type":"print","value":"1174-5886"},{"type":"electronic","value":"1179-6901"}],"subject":[],"published":{"date-parts":[[2019,7,12]]},"assertion":[{"value":"12 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The original study (NCT00508404) and performance of the retrospective analyses described here were supported by Amgen Inc, and medical writing assistance was funded by Amgen (Europe) GmbH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Claus-Henning K\u00f6hne has received honoraria from Amgen, Bayer, Merck, Pfizer and Servier. Meinolf Karthaus has consulting\/advisory roles and has participated in steering committees for Amgen and has received travel\/accommodation\/expenses from Amgen. Laurent Mineur has consulting\/advisory roles for Bayer and Merck, and has received travel\/accommodation\/expenses from Merck and Ipsen, honoraria from Amgen, Bayer, Ipsen, Merck and Sanofi, and research funding from Chugai, Merck and Sanofi. Josef Thaler has received honoraria and research funding from Amgen. Marc Van den Eynde has consulting\/advisory roles for Amgen, Bayer, Merck and Servier, and has received travel\/accommodation\/expenses from Amgen, Bayer, Merck and Roche, honoraria from Amgen, Bayer, Merck, Roche, Sanofi and Servier, and research funding from Roche. Javier Gallego has consulting\/advisory roles for Amgen, Bayer, Celgene, Lilly, Merck Serono, Roche and Sanofi. Reija Koukakis is an Amgen Ltd. employee and owns restricted shares in Amgen. Marloes Berkhout is an Amgen (Europe) GmbH employee and owns restricted shares in Amgen. Ralf-Dieter Hofheinz has received honoraria (lecturer fees) and clinical trial funding from Amgen Ltd. and Merck.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institution and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study. No additional consent was required for these retrospective analyses.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"RK and MB were involved in the conception and design of the analyses. RK performed the statistical analyses. C-HK, MK, LM, JT and R-DH collected study data. All authors contributed to the interpretation of the data, the preparation and revision of the manuscript, and approved the final version.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"There is a plan to share data. This may include de-identified individual patient data for variables necessary to address the specific research question in an approved data-sharing request; also related data dictionaries, study protocol, statistical analysis plan, informed consent form and\/or clinical study report. Data sharing requests relating to data in this manuscript will be considered after the publication date and (1) this product and indication (or other new use) have been granted marketing authorisation in both the USA and Europe or (2) clinical development discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for these data. Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study\/studies in scope, endpoints\/outcomes of interest, statistical analysis plan, data requirements, publication plan and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. A committee of internal advisors reviews requests. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymised individual patient data and\/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}}]}}